Figure 7

Protein–ligand interaction mapping for Sirt2 docked with selected FDA-approved drugs, i.e., (a) Canagliflozin, (b) Flibanserin, (c) Ezetimibe, (d) Pimozide, (e) Fluphenazine, (f) Droperidol, (g) Osimertinib, (h) Pioglitazone, (i) Formoterol, and (j) Nintedanib, extracted from respective 100 ns MD trajectories.